Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse.
Warner
L M
LM
Inflammatory Diseases Division, Wyeth-Ayerst Research, Princeton, NJ 08543, USA.
Cummons
T
T
Nolan
L
L
Sehgal
S N
SN
D000818:Animals; D016572:Cyclosporine / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000096:biosynthesis; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008815:Mice, Inbred Strains; D011090:Polyenes / Q000627:therapeutic use*; D020123:Sirolimus; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000378:metabolism
D007166:Immunosuppressive Agents; D007376:Interleukin-2; D011090:Polyenes; D016572:Cyclosporine; D020123:Sirolimus